Objective Capital Partners Announced as Finalist for the Valuation Firm of The Year in the 17th Annual M&A Advisor Awards

Posted September 18, 2018 by OCP | Post a Comment

San Diego, September 14, 2018 – Objective Capital Partners, a leading middle-market M&A firm, has been nationally recognized as a Valuation Firm of the Year Award finalist by M&A Advisor for their valuation work in Life Sciences, Healthcare, and Technology.


Press News

OCP Is Leading Growth in the San Diego Life Science Community

Posted June 04, 2018 by OCP | Post a Comment

"Working with life science companies is not like serving other industries. There are myriad legal and financial eccentricities - accounting for multiple financing sources makes accounting especially complex, for instances and protecting intellectual property is key. Early-stage companies may need their hand held as they focus on the science and outsource everything else." San Diego Business Journal


Life Sciences, Healthcare, Capital Raise & Financing, Business Valuation, Strategic Advisory, Press News

Objective Capital Partners Welcomes Matt Ramirez as Associate

Posted May 10, 2018 by OCP | Post a Comment

We are excited to announce the addition of experienced finance professional, Matt Ramirez, to the firm. Matt brings with him a great depth of finance experience having served previously as a Senior Associate with Ernst & Young's Assurance Services Practice where he led teams in the execution of public and private company financial statement audits.


Press News

Objective Capital Advises Healthcare IT Company on Its Sale to Kinderhook Industries

Posted May 01, 2018 by OCP | Post a Comment

Los Angeles, CA April 24, 2018 — Objective Capital Partners, a leading middle market investment banking firm, is pleased to announce that it served as the exclusive financial advisor to StudyKIK LLC, a rapidly-growing healthcare IT company, on its acquisition by Kinderhook Industries LLC.

“Matt and his team have done a remarkable job in creating a leading patient recruiting platform which is having an enormous impact by making it dramatically more efficient for clinical trial companies to find and engage the high-fit trial volunteers they need to bring new and innovative treatments to market,” said Channing Hamlet, Managing Director of Objective Capital Partners. “We are privileged to have had this opportunity to help StudyKIK and couldn’t be more excited about the future of the company.”


Life Sciences, Healthcare, Strategic Advisory, Press News

Symple Surgical, Inc. Retains Objective Capital Partners to Explore Strategic and Financial Partnerships

Posted April 17, 2018 by OCP | Post a Comment

San Diego, CA and Flagstaff, AZ, April 12, 2018: — Symple Surgical, Inc., a privately-held, early-stage medical device company focused on developing novel therapeutic technologies using microwave technology for treatment of life-threatening chronic conditions, is pleased to the announce that they have retained Objective Capital Partners as their exclusive financial advisor. Objective Capital Partners, a middle-market Investment Banking firm located in Southern California and focused on mergers & acquisitions (M&A), strategic advisory, capital financing and valuation services, will seek to identify strategic partnerships and financial investors for the Company to progress their lead product Grizzly™ targeting pre-cancerous cells in the elimination of Barrett's Esophagus and Esophageal Adenocarcinoma, the fastest growing cancer worldwide.

Barrett’s Esophagus (BE) is a premalignant condition caused by stomach acid or gastrointestinal reflux disease (GERD) mutating healthy cells in the lower esophagus into Barrett’s cells.  Approximately 90% of Esophageal Adenocarcinoma (EAC) patients do not receive a prior diagnosis of Barrett’s Esophagus (BE). BE affect’s more than 12 million American adults, and is associated with a 30-fold increased risk of developing EAC. This new treatment will provide an alternative to the Radiofrequency Ablation Technology (“RFA”) and cryoablation technologies currently in use for treatment of BE thereby reducing the number of episodes of treatment and providing unparalleled user control for adequate cell removal.


Press News, Strategic Advisory, Life Sciences, Healthcare

Objective Capital Partners Promotes Michael Kim to Managing Director

Posted April 06, 2018 by OCP | Post a Comment

San Diego, April 9, 2018 — Objective Capital Partners is pleased to announce the promotion of Michael Kim to Managing Director. Michael contributes over 15 years of mergers & acquisitions (M&A) and corporate finance experience across numerous industries including technology, consumer, and business services. He was also recognized in 2016 by M&A Advisor as a M&A Advisor Emerging Leaders Award Winner.

Mr Kim joined Objective Capital in 2015 and has been responsible for all aspects of  transaction lifecycle including client sourcing, due diligence, negotiation, valuation analyses, and transaction closings. In his new role, Michael will continue serving the firm’s clients in the areas of transaction origination, analysis and execution.


Press News

Objective Capital's David H. Crean Named 2017 Thought Leader of the Year

Posted January 29, 2018 by OCP | Post a Comment

The Alliance of Merger & Acquisition Advisors® (AM&AA)

San Diego, January 30, 2018 — Objective Capital Partners, a middle-market M&A Advisory Firm located in Southern California, is pleased to announce that David H. Crean, Ph.D., Managing Director of the firm’s thriving Life Sciences and Healthcare practice, has been selected as the winner of the 2017 Thought Leader of the Year Award by The Alliance of Merger & Acquisition Advisors® (AM&AA).

The AM&AA recognized that “David’s thought leadership is materially expanding the investment banker’s role in serving life sciences companies and providing these companies with a highly attractive, non-diluting alternative to hard-to-secure venture capital financing.”

“We are observing life sciences and healthcare companies increasing engaging specialized investment banking teams with deep industry experience to gain a strategic advantage,” said Trever Acers, Managing Director at Objective Capital Partners.  “Specialized professionals such as David and his team members at Objective Capital are engaged by experienced Life Sciences executives to significantly improve the value, probability and speed of their M&A, strategic partnering, and growth capital objectives.  David is at the forefront of this change, leveraging his decades of industry experience with best-in-class investment banking capabilities to provide CEO with highly actionable strategic guidance."


Healthcare, Life Sciences, Awards, Press News

Community Insights: Understanding Options for Your Business

Posted January 23, 2018 by admin | Post a Comment

San Diego, CA- January 23, 2018 – Objective Capital Partners, a middle-market M&A Advisory Firm located in Southern California, is pleased to announce that Trever Acers, a Managing Director at the firm, will be presenting at a series of monthly Community Insights alongside Greg Banner, Vice President at Asset Preservation Strategies. This series of discussions is targeted towards business owners to help them understand planning options for their business. The Community Insights series is designed to introduce estate, financial, business, real estate as well as long-term care planning clients to the various options that facilitate achieving their goals.

There is no cost to attend the Community Insights series but you must register online at:



Press News

Life Sciences Tools, Diagnostics, & Services Industry Report 11/2017

Posted November 14, 2017 by OCP | Post a Comment

Objective Capital Partners has expertise in four industry sectors: Business Services, Consumer, Life Sciences & Healthcare, and Technology. As part of our ongoing efforts in the Life Sciences and Healthcare space, we have developed specific expertise in Life Science Tools. In fact, we recently closed an interesting transaction in the life sciences services space.


Press News, Life Sciences, Healthcare

Bio Buck$ Fast Forward: A Start-up’s Guide to Investment Banks

Posted November 05, 2017 by OCP | Post a Comment

Objective Capital’s David H. Crean to Serve as Guest Panelist at LaunchBio Event, November 14, 2017

San Diego, November 9, 2017 — Objective Capital Partners, a middle market M&A Advisory Firm located in Southern California, is pleased to announce that David H. Crean, Ph.D., one of its Managing Directors who heads its thriving life science and healthcare practice, has been invited to speak as a guest panelist at LaunchBio Series Event for life science companies entitled BIO Buck$ Fast Forward: A Start-ups Guide to Investment Banks. Dr. Crean will be joined by Charlie Adams, Cantor Fitzgerald and Tony Grover, VP of Business Development at Banyan Biomarker.


Press News, Capital Raise & Financing, Sell-Side M&A

This article is provided for informational purposes only and does not constitute an offer, invitation or recommendation to buy, sell, subscribe for or issue any securities. While the information provided herein is believed to be accurate and reliable, Objective Capital Partners and BA Securities, LLC makes no representations or warranties, expressed or implied, as to the accuracy or completeness of such information. It should not be construed as investment, legal, or tax advice and may not be reproduced or distributed to any person.

Our Services

Learn about our services and how we can help you sell your business successfully.


Contact Us

San Diego Office:
3636 Nobel Dr., Suite 160
San Diego, CA 92122

Los Angeles Office:
10100 Santa Monica Blvd., Suite 300
Los Angeles, CA 90067

Trever Acers
Managing Director
858.663.8662 telephone

Channing Hamlet
Managing Director
858.342.4939 telephone

David H. Crean, Ph.D.
Managing Director
858.461.9490 telephone

Jack J. Florio
Managing Director
858.864.4339 telephone